Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
TETRANEURON logo — A new path for Alzheimer's disease

TETRANEURON

A new path for Alzheimer's disease

Founded 2012 Spain Spain 18 employees Undisclosed Total: $8.50M Biotechnology, Pharmaceutical

General Information

Company Name TETRANEURON
Founded Year 2012
Location Spain Spain +2
Employees 18
Industries Biotechnology, Pharmaceutical
Funding Stage Undisclosed
Social

Get notified when TETRANEURON moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TETRANEURON

TETRANEURON is a biotechnology and pharmaceutical startup founded in 2012 with its headquarters in Spain. The company is dedicated to pioneering a novel approach in the treatment and diagnosis of Alzheimer's disease. With the slogan "A new path for Alzheimer's disease," TETRANEURON aims to make significant strides in this field through the development of a disruptive Gene Therapy for Alzheimer's disease and an Early Biomarker for this prevalent neurodegenerative condition. In its latest milestone, TETRANEURON successfully secured a substantial €5.00M in its most recent funding round on 27 December 2022. This financial backing is poised to fuel the company's advancements and propel its innovations in combating Alzheimer's disease. As TETRANEURON continues to push the boundaries of biotechnology and pharmaceuticals, it stands as a promising player in the critical endeavor to address Alzheimer's disease with cutting-edge solutions.

Taxonomy: Drug discovery, Gene therapy, Alzheimer's disease, Neurodegenerative disease, Biomarker development, Healthcare innovation, Medical research, Neuroscience, Start-up, Investment opportunities

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Funding Round •••••• - 27 Dec 2022
Debt Financing •••••• 2
Investor
•••• •••• 		27 Dec 2021
Funding Round •••••• - 29 Jun 2021

TETRANEURON Alternatives & Competitors

TETRANEURON vs
RespiQ
RespiQ The Netherlands

Smart breath testing for better health.

Grant
11 employees
Biotechnology
TETRANEURON vs
MitoRx Therapeutics
MitoRx Therapeutics United Kingdom

Developing new treatments to restore healthy mitochondrial metabolism in patients living with high-r...

Seed
17 employees
Biotechnology, Health and Wellness
TETRANEURON vs
Avolynt, Inc.
Avolynt, Inc.

Avolynt is a clinical stage pharmaceutical company developing novel therapeutics for the treatment o...

Grant
2 employees
Biotechnology, Health Care

FAQ About TETRANEURON

A new path for Alzheimer's disease
TETRANEURON was founded in 2012.
TETRANEURON is headquartered in Spain.
TETRANEURON operates in the following industries: Biotechnology, Pharmaceutical.
TETRANEURON has approximately 18 employees.
TETRANEURON has completed 3 funding rounds, raising a total of $8.50M. The latest funding stage is Undisclosed.
Top alternatives and competitors to TETRANEURON include RespiQ, MitoRx Therapeutics, Avolynt, Inc., Galaxy Diagnostics, Inc., Specialty Renal Products Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TETRANEURON and RespiQ are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TETRANEURON and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy